bamlanivimab-etesevimab
Selected indexed studies
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. (N Engl J Med, 2021) [PMID:34260849]
- Do we need bamlanivimab? Is etesevimab a key to treating Covid-19? (Expert Opin Biol Ther, 2021) [PMID:34555986]
- Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database. (Expert Opin Drug Saf, 2023) [PMID:36178050]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. (2021) pubmed
- Do we need bamlanivimab? Is etesevimab a key to treating Covid-19? (2021) pubmed
- Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database. (2023) pubmed
- COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations. (2023) pubmed
- Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection. (2022) pubmed
- Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern. (2021) pubmed
- Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together. (2021) pubmed
- Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. (2021) pubmed
- Safety of Intradialytic Bamlanivimab/Etesevimab Administration in Two COVID-19 Dialysis Outpatients. (2022) pubmed
- Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report. (2022) pubmed